Coherus Oncology (NASDAQ:CHRS) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Coherus Oncology (NASDAQ:CHRS) released its earnings results on Monday. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02, FiscalAI reports. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%. The firm had revenue of $14.27 million during the quarter, compared to analysts’ expectations of $15.90 million.

Coherus Oncology Price Performance

Shares of NASDAQ:CHRS traded up $0.05 on Monday, reaching $0.82. The company’s stock had a trading volume of 2,188,007 shares, compared to its average volume of 1,515,357. Coherus Oncology has a 52-week low of $0.73 and a 52-week high of $2.62. The company has a market cap of $126.32 million, a P/E ratio of -0.79 and a beta of 1.03. The company has a 50-day simple moving average of $1.14 and a 200 day simple moving average of $1.51. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.70 and a current ratio of 1.77.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CHRS. Weiss Ratings raised shares of Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 26th. HC Wainwright started coverage on shares of Coherus Oncology in a research note on Thursday, October 29th. They set a “buy” rating for the company. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

About Coherus Oncology

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.